ClinicalTrials.gg
Not yet recruitingNCT07479251Updated Mar 23, 2026

Glycaemic Index Measurement of an Oral Nutritional Supplement With Biomarker Assessment and Lifestyle Monitoring in Healthy Participants

An interventional study of ONS and glucose in Healthy Participants, sponsored by Fresenius Kabi. Not yet recruiting. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Fresenius Kabi · Not applicable, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This clinical trial evaluates the postprandial glycaemic response to an Oral Nutritional Supplement (ONS), a Food for Special Medical Purposes (FSMP), in healthy adults. The study uses a crossover design comparing the ONS to the reference product glucose.

Each participant will consume both test and reference products on three separate occasions each, overall on six test days.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Fresenius Kabi is the lead sponsor of 51 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 and ≤60 years, adult healthy Caucasian or Chinese participants
  • Stable body weight within the between 18.5 kg/m2 and 27.9 kg/m2 (inclusive)
  • \< 6%/\< 42 mmol/mol

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating,
  • Body fat percentage exceeding 30%,
  • Known history of metabolic diseases or diabetes mellitus,
  • Major medical or surgical event requiring hospitalization within the preceding 3 months
  • Medical condition(s) or medication(s) or herbal effects known to affect glucose regulation, tolerance or appetite and/or which influence digestion and absorption of nutrients (excluding oral ),
  • Use of , protease inhibitors, amphetamines or antipsychotics
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Group A (Treatment sequence: Glucose, ONS, Glucose, ONS, Glucose, ONS)

    Participants will receive the test product and the control product alternately. They will be randomly assigned to one of the two treatment sequence groups with 15 participants in each group. The randomization will be stratified by race/ethnicity (Chinese, Caucasian).

    Dietary Supplement: ONS · Other: glucose

  • Other
    Group B (Treatment sequence: ONS, Glucose, ONS, Glucose, ONS, Glucose)

    Participants will receive the test product and the control product alternately. They will be randomly assigned to one of the two treatment sequence groups with 15 participants in each group. The randomization will be stratified by race/ethnicity (Chinese, Caucasian).

    Dietary Supplement: ONS · Other: glucose

Interventions

  • Dietary supplementONS

    Each administration of the test product (ONS) will represent 25 g of glycaemic carbohydrates.

  • Otherglucose

    The test product will be compared with the reference product glucose (glucose monohydrate dissolved in 250 ml water). Each administration of the reference product will represent 25 g of glycaemic carbohydrates.

06

What researchers measure

Primary outcomes

  1. Glycaemic Index (GI) of ONS

    Three GIs for each repeated test of the ONS (based on capillary blood glucose) and their average GI (mean value) will be calculated as per ISO 26642.

    Time frame: Blood samples will be obtained at -5, 0, 15, 30, 45, 60, 90, and 120 minutes.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 18, 2026
StartEst.
Mar 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07479251
Lead sponsor
Fresenius Kabi
Collaborators
Oxford Brookes University
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
Mar 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 23, 2026

Study contacts

Sangeetha Thondre, Dr
Contact
pthondre@brookes.ac.uk
+44 1865 534136

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion